Live Breaking News & Updates on Nasdaq Krbp|Page 3

Stay updated with breaking news from Nasdaq krbp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zacks Investment Research Downgrades Kiromic BioPharma (NASDAQ:KRBP) to Sell

Kiromic BioPharma (NASDAQ:KRBP – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Kiromic BioPharma Inc. is a discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on […] ....

United States , Kiromic Biopharma , Kiromic Biopharma Inc , Zacks Investment Research , Renaissance Technologies , J Harrison Partners Inc , Warberg Asset Management , Zeke Capital Advisors , Kiromic Biopharma Company Profile Get Rating , Get Rating , Asset Management , Partners Inc , Capital Advisors , Biopharma Company Profile , Nasdaq Krbp ,

Kiromic BioPharma, Inc. (NASDAQ:KRBP) to Post Q1 2023 Earnings of ($0.43) Per Share, Diamond Equity Forecasts

Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) – Equities researchers at Diamond Equity issued their Q1 2023 earnings per share (EPS) estimates for shares of Kiromic BioPharma in a research report issued to clients and investors on Thursday, May 19th. Diamond Equity analyst H. Diamond forecasts that the company will post earnings of ($0.43) per […] ....

Kiromic Biopharma , Kiromic Biopharma Inc , J Harrison Partners Inc , Warberg Asset Management , Renaissance Technologies , Kiromic Biopharma Company Profile Get Rating , Zeke Capital Advisors , Get Rating , Diamond Equity , Asset Management , Partners Inc , Capital Advisors , Biopharma Company Profile , Nasdaq Krbp , Earnings Estimates ,

Kiromic BioPharma, Inc. (NASDAQ:KRBP) Sees Significant Growth in Short Interest

Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 333,000 shares, a growth of 216.5% from the February 28th total of 105,200 shares. Based on an average daily trading volume, of 296,500 shares, […] ....

Kiromic Biopharma , Kiromic Biopharma Inc , Capital Management , Intellectus Partners , Kiromic Biopharma Company Profile Get Rating , Vanguard Group Inc , Zeke Capital Advisors , Get Rating , Capital Advisors , Biopharma Company Profile , Nasdaq Krbp ,